Renvela 400mg Tablet

By Renvela

Rx

1 Tablet in a Strip

Composition icon

Composition

Sevelamer(400mg)

Manufacturer - Sanofi India Ltd icon

Manufacturer - Sanofi India Ltd

Sanofi House, CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Expires on or after icon

Expires on or after

July, 2025

About Renvela 400mg Tablet

Renvela 400mg Tablet is a medication specifically designed to treat elevated levels of phosphate in the blood. It is primarily prescribed for individuals undergoing dialysis due to severe kidney disease. The main function of Renvela 400mg Tablet is to block the absorption of phosphate from the intestines, thereby reducing the phosphate levels in the blood.

To effectively benefit from Renvela 400mg Tablet, it is recommended to take the medication with food. Patients should strictly adhere to the dosage and duration as prescribed by their healthcare provider. Consistency is key in maximizing the therapeutic effects of the medicine, so it is advised to take it regularly at a fixed time each day.

Like any medication, Renvela 400mg Tablet may come with some side effects. These can include nausea, vomiting, abdominal pain, constipation, and diarrhea. Additionally, there is a risk of experiencing low levels of calcium, folic acid, and certain vitamins in the blood. In such cases, it is important to follow the doctor's guidance on taking necessary supplements to maintain overall health.

Moving on to Renvela 800mg Tablet, this medication contains Sevelamer, which falls under the category of Phosphate Binding Agents. It is commonly prescribed to manage serum phosphorous levels in individuals with chronic kidney disease who are undergoing dialysis. The leading cause of elevated phosphorous levels in such patients is renal failure, leading to reduced phosphate filtration and consequent increase in serum levels.

During the course of treatment with Renvela 800mg Tablet, doctors may recommend certain tests to monitor for any potential side effects. It is crucial to adhere to the prescribed diet plan provided by the medical professional for optimal results.

It is important to note that Renvela 800mg Tablet is not suitable for patients with low phosphorus levels in the blood or bowel obstruction. Caution should also be exercised when using this medication in individuals facing swallowing difficulties, stomach and bowel motility issues, or who have undergone major bowel surgery. Pregnant women should use Renvela 800mg Tablet only if deemed necessary by a healthcare provider. It is advisable to consult a doctor before taking this medication while breastfeeding, as its effects on the baby are not yet established. Renvela 800mg Tablet is not intended for use in children or adolescents under 18 years of age.

Common side effects of Renvela 800mg Tablet may include constipation, vomiting, abdominal pain, nausea, diarrhea, indigestion, and flatulence. Should any of these symptoms persist or worsen, it is advisable to seek guidance from a healthcare professional.


Disclaimer

The information provided on this website is to the best of our abilities to ensure it is accurate, reliable, and reviewed by a team of professionals. It should not be used to diagnose, prevent, or cure any health problem. The information presented here is not intended to create a doctor-patient relationship or replace a registered medical practitioner's advice, diagnosis, or treatment. The absence or provision of any information or warning regarding any medicine should not be assumed as an implied or explicit assurance of safety or efficacy. We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition. Do not ignore professional medical advice or delay seeking it based on the content encountered on our website. We intend to support, not replace, the doctor-patient relationship.

1087.5

Inclusive of all taxes

Content verified by

chevron-right

Dr. Gowri Kulkarni

MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)

Last update on 01-Oct-2024